IP Library Granted Patent US 9,970,024
Granted Patent B2
US 9,970,024 · App. 14/653,144 · Granted May 15, 2018

RNA-guided human genome engineering

Inventors: George M. Church (Brookline, MA); Prashant Mali (Somerville, MA); Luhan Yang (Somerville, MA)
Assignee: President and Fellows of Harvard College
C12N15/85C12N9/22C12N15/01C12N15/10C12N15/102C12N15/1024C12N15/63C12N15/81C12N15/8201C12N15/87C12N15/90C12N15/907C12N2800/80C12N2810/55C12Y301/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,970,024
App. No.
14/653,144
Granted
May 15, 2018
Kind
B2
Abstract

A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.

Claims (7)

1. A method of visualizing a target nucleic acid sequence in a eukaryotic cell comprising providing to the eukaryotic cell a guide RNA complementary to the target nucleic acid sequence, and providing to the cell a Cas 9 protein having inactive nuclease domains and having a fluorescent molecule attached thereto, wherein the guide RNA and the Cas 9 protein having the fluorescent molecule attached thereto form a complex at the target nucleic acid sequence and is visualized.

2. The method of claim 1 wherein the fluorescent molecule is a fluorescent protein, a protein bound organic fluorophore, a nucleic acid bound organic fluorophore, a quantum dot, a molecular beacon, an echo probe or a molecular beacon replacement.

3. The method of claim 1 wherein the eukaryotic cell is a yeast cell, a plant cell, a mammalian cell, a stem cell or a human cell.

4. The method of claim 1 wherein the RNA includes between about 10 to about 250 nucleotides.

5. The method of claim 1 wherein the RNA includes between about 20 to about 100 nucleotides.

6. The method of claim 1 wherein the eukaryotic cell is provided with a plurality of guide RNAs complementary to different target nucleic acids, wherein the guide RNAs and the Cas 9 protein having the fluorescent molecule attached thereto form complexes at the target nucleic acid sequences and are visualized.

7. The method of claim 1 wherein the guide RNA is provided to the eukaryotic cell by introducing to the eukaryotic cell a nucleic acid encoding the guide RNA, wherein the Cas 9 protein having the fluorescent molecule attached thereto is provided to the eukaryotic cell by introducing to the eukaryotic cell a nucleic acid encoding the Cas 9 protein having the fluorescent molecule attached thereto, and wherein the eukaryotic cell expresses the guide RNA and the Cas 9 protein having the fluorescent molecule attached thereto.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2016
From: CHURCH, GEORGE M.; MALI, PRASHANT; YANG, LUHAN
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 037529/0879 →
CONFIRMATORY LICENSE Recorded Jul 7, 2015
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036074/0244 →
Continuity (3)
Provisional Application 61779169 · Mar 13, 2013
Provisional Application 61738355 · Dec 17, 2012
Related Publication 20160032274A1 · Feb 4, 2016